AstraZeneca announced positive Phase 3 EMERALD-3 trial results for its STRIDE immunotherapy regimen combined with lenvatinib and TACE in treating unresectable hepatocellular carcinoma. The combination achieved a 30% reduction in disease progression or death risk and median progression-free survival of 13 months versus 9.8 months with TACE alone, with an encouraging overall survival trend. However, AstraZeneca shares fell 2.69% on the news.

Velan Capital Investment Management LP sold 140,000 shares of Mineralys Therapeutics in Q1 2026, valued at approximately $4.11 million, reducing its stake to 11,000 shares. Despite the fund's reduction, Mineralys stock has surged 87.84% over the past year. The clinical-stage biotech company is awaiting FDA approval for its lead candidate lorundrostat by December 22, 2026, and maintains $646 million in cash.

The ESR1-mutated metastatic breast cancer market is projected to grow at 9.6% CAGR through 2036, driven by rising prevalence of endocrine-resistant HR-positive/HER2-negative breast cancer and adoption of precision oncology. Novel oral SERDs and targeted agents from major pharmaceutical companies are reshaping the treatment landscape. The market was valued at USD 1.5 billion in 2025, with the US representing the largest market share. Recent FDA approvals include VEPPANU (vepdegestrant), the first PROTAC therapy, while several emerging therapies are in clinical development.

The global protein synthesis research market is experiencing accelerating growth driven by increased investment in cell and gene therapy research, rising chronic disease prevalence, and expanding healthcare budgets. North America leads with 42.8% market share, while Asia-Pacific infrastructure expansion presents significant growth opportunities. Key market drivers include strong late-stage therapy pipelines and government support through initiatives like the CHIPS and Science Act.

The myasthenia gravis market is projected to grow from USD 6 billion in 2025 to over USD 16 billion by 2036, driven by rising diagnosed prevalence, improved diagnostics, and an expanding pipeline of targeted biologic therapies including FcRn inhibitors, complement inhibitors, and CAR-T cell therapies. The market is currently led by argenx and UCB, with numerous emerging candidates in late-stage development expected to significantly accelerate growth.

Research presented at the 2026 AUA Annual Meeting highlights progress in bladder cancer care, including findings that adding immunotherapy drug durvalumab to BCG treatment delays disease progression and helps patients avoid bladder removal surgery. Studies also reveal environmental risk factors, including air pollution and e-cigarette use, may contribute to bladder cancer development, with e-cigarette users showing earlier diagnosis ages.

SAPHNELO (Anifrolumab), a first-in-class type I interferon receptor blockade monoclonal antibody for moderate-to-severe SLE, is projected to see strong market growth through 2034 across major markets. The drug generated approximately $483 million in the first nine months of 2025 and has been approved in over 70 countries. However, the FDA issued a Complete Response Letter in February 2026 for the subcutaneous formulation, which AstraZeneca is working to address.

AstraZeneca announced interim Phase 3 VOLGA trial results showing that perioperative treatment with Imfinzi (durvalumab) and neoadjuvant enfortumab vedotin significantly improved event-free survival and overall survival in patients with muscle-invasive bladder cancer who were ineligible for cisplatin-based chemotherapy. The combination demonstrated statistically significant benefits in key endpoints with a consistent safety profile. However, one treatment arm showed a favorable trend in overall survival that did not reach statistical significance.

Impact Therapeutics debuted on the Hong Kong stock market on May 13, 2026, with shares doubling on the first day after an oversubscribed IPO. The biotech company raised HK$844 million to fund development of senaparib, a PARP inhibitor for advanced ovarian cancer approved in China. While the drug shows promise with a 57% reduction in disease progression risk, the company remains unprofitable with significant R&D spending and faces competition from established players like AstraZeneca and Hengrui Pharma in the growing synthetic lethality drug market.

Owkin and AstraZeneca signed a three-year licensing agreement to develop specialized biopharma AI agents using Owkin's K Pro platform. The AI agents will support competitive intelligence and data-driven decision-making within AstraZeneca's infrastructure. The expansion builds on prior collaboration involving an AI gBRCA pre-screening solution for breast cancer patients.

The sepsis drug development pipeline shows strong activity with 25+ pharmaceutical companies developing 30+ pipeline drugs across various clinical stages. Key players include Vivacelle Bio, Inotrem, Sobi, AUROBAC Therapeutics, Novartis, AstraZeneca, and Bayer, with approximately 7+ drugs in late-stage development. Recent milestones include AUROBAC's Phase I completion of ATX101 and FDA Fast Track designation for Enibarcimab, reflecting progress in addressing this high-mortality, high-unmet-need indication.

AstraZeneca announced that its investigational drug eneboparatide (AZP-3601) met the primary endpoint in the Phase 3 CALYPSO trial for chronic hypoparathyroidism. The therapy demonstrated that 31.1% of patients achieved normal calcium levels and independence from vitamin D and calcium supplements at week 24, compared to 5.9% in the placebo group. The drug was generally well-tolerated, with benefits maintained through 52 weeks, though immunogenicity was observed in some patients.